Emerging Biotechs Adopt Pre-Configured Veeva Software to Scale
More than 175 emerging biotechs have transitioned to Veeva Basics, a suite of pre-configured applications designed to accelerate drug development. By replacing manual, paper-based workflows with validated digital systems, these high-growth companies aim to bridge the operational gap between early-stage research and commercial-scale drug delivery without requiring large IT departments.
The platform provides unified, end-to-end support for clinical, regulatory, quality, medical, and commercial operations. Bryan Ball, chief technology operations officer at Whitehawk Therapeutics, noted that the software allowed his sub-40-employee firm to bypass complex customizations while maintaining compliance during the development of antibody-drug conjugates. The system is built on the existing Vault Platform, allowing smaller firms to retain their infrastructure as they expand.
Beyond general operational efficiency, the software is altering regulatory strategy. Companies like Structure Therapeutics are utilizing Veeva Submissions Publishing Basics to bring previously outsourced publishing in-house. This shift provides firms with greater control over FDA submissions and tighter quality oversight. According to Darryl Clarke, global head of regulatory operations at Structure Therapeutics, the move has resulted in sharper quality control and reduced regulatory timelines, providing a scalable foundation for future growth.
Comments (0)
No comments yet. Be the first!